A Phase 2 interventional study of Cisplatin 40 mg/m2 and Cisplatin 100 mg/m2 in Head and Neck Squamous Cell Carcinoma, sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. Completed at 1 site in Bangladesh. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck — 19 open to participants now, 31 under way, 5 of them phase 3. Cisplatin · Squamous Cell Carcinoma of Head and Neck.
Among the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, this one is the 45th largest by enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2024, is one of 70 in phase 2, and was the 91st registered.
2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →19 of the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+
Sara Medek · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
Rui You · Sites in China
Ages 18–75
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
115 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 83 · Phase 3 18
First in 1988; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 48 across 1,657 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 47 across the 107 interventional studies. Of the 74 that completed or were terminated, 28 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 115 have an industry lead sponsor. The 10 most frequent:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh is the lead sponsor of 128 studies on the registry; 22 are open to participants now.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh has 1 study filed under Squamous Cell Carcinoma of Head and Neck — fewer than ten, so there is no comparison to draw.
3 of the studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04502407Cedars-Sinai Medical CenterTrial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer | 2026-12-15 |
| NCT06323460Ohio State University Comprehensive Cancer CenterAdaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer | 2026-12-31 |
| NCT07371234Rui YouLow-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma | 2027-01-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 115 studies testing cisplatin in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to compare treatment responses and toxicities of concurrent chemo-radiation with weekly and three weekly Cisplatin in locally advanced Head \& Neck Cancer. Half of the participants received Cisplatin (40 mg/m2) weekly with radiotherapy, while the other half received Cisplatin (100 mg/m2) thrice weekly with radiotherapy. Radiotherapy continued five days per week for six and half weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly Cisplatin
Drug: Cisplatin 40 mg/m2
Three weekly Cisplatin
Drug: Cisplatin 100 mg/m2
Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Cisplatin 40 mg /m2 intravenous infusion delivered concurrently with radiotherapy on a weekly basis.
Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Cisplatin 100 mg/m2 intravenous infusion delivered on a three weekly basis on days 1, 22 and 43 delivered concurrently with radiotherapy.
Loco-regional Tumor Control After Completion of Treatment
Response Evaluation Criteria in Solid Tumors was used to measure outcome: 1. Complete response (CR): Disappearance of all target lesions. 2. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. 3. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions. 4. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: 6 months
Distribution of the Patients by Oral Mucositis
Radiation Therapy Oncology Group (RTOG) toxicity criteria was used to measure toxicities related to oral mucosa. Grade I: Irritation / may experience mild pain not requiring analgesic. Grade II: Patchy mucositis that may produce an inflammatory serosanguinous discharge / may experience moderate pain requiring analgesia. Grade III: Confluent fibrinous mucositis / may include severe pain requiring narcotic. Grade IV: Ulceration, hemorrhage or necrosis.
Time frame: 8 months
| Milestone | Arm A | Arm B |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
Response Evaluation Criteria in Solid Tumors was used to measure outcome: 1. Complete response (CR): Disappearance of all target lesions. 2. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. 3. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions. 4. Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Arm A | Arm B |
|---|---|---|
| Complete response | 19 | 23 |
| Partial response | 8 | 5 |
| Progressive disease | 3 | 2 |
Radiation Therapy Oncology Group (RTOG) toxicity criteria was used to measure toxicities related to oral mucosa. Grade I: Irritation / may experience mild pain not requiring analgesic. Grade II: Patchy mucositis that may produce an inflammatory serosanguinous discharge / may experience moderate pain requiring analgesia. Grade III: Confluent fibrinous mucositis / may include severe pain requiring narcotic. Grade IV: Ulceration, hemorrhage or necrosis.
| Participants | Arm A | Arm B |
|---|---|---|
| Grade I oral mucositis | 4 | 16 |
| Grade II oral mucositis | 18 | 10 |
| Grade III oral mucositis | 8 | 4 |
Collected over 8 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A | 0/30 (0%) | 0/30 (0%) | 30/30 (100%) |
| Arm B | 0/30 (0%) | 0/30 (0%) | 30/30 (100%) |
| Event | Arm A | Arm B |
|---|---|---|
| VomitingGeneral disorders | 22/30 | 20/30 |
| AnemiaBlood and lymphatic system disorders | 8/30 | 10/30 |
| Age, Categorical(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 24 | 26 | 50 |
| >=65 years | 6 | 4 | 10 |
| Sex: Female, Male(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Female | 10 | 9 | 19 |
| Male | 20 | 21 | 41 |
| Race and Ethnicity Not Collected(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Bangladesh | 30 | 30 | 60 |
| Occupational status(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Farmers | 10 | 12 | 22 |
| Service holders | 5 | 4 | 9 |
| Businessmen | 4 | 6 | 10 |
| Housewives | 7 | 5 | 12 |
| Unemployed | 4 | 3 | 7 |
| Smoking habit(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Yes | 23 | 25 | 48 |
| No | 7 | 5 | 12 |
| Primary site of tumor(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Oral cavity | 9 | 8 | 17 |
| Larynx | 6 | 9 | 15 |
| Oropharynx | 8 | 6 | 14 |
| Hypopharynx | 4 | 5 | 9 |
| Others | 3 | 2 | 5 |
| Stage of disease(Participants) | Arm A | Arm B | Total |
|---|---|---|---|
| Stage III | 11 | 13 | 24 |
| Stage IVA | 10 | 11 | 21 |
| Stage IVB | 9 | 6 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol
Access criteria: To request an electronic copy send email to dr.iurahim@gmail.com
Ran from Jan 2024 to primary completion in Dec 2024, 11 months.
Results were first posted in Oct 2026, 1 year 9 months after primary completion.
Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 11 months is below that.
Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jul 2017 → Jan 2024, primary completion Jun 2018 → Dec 2024 and completion Dec 2018 → Jun 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cisplatin
Squamous Cell Carcinoma of Head and Neck →
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh →